Pharmacotherapy of glaucoma in terms of evidence-based medicine
Glaucoma is a disease associated with increased intraocular pressure (IOP). Of the pharmacological agents for treating glaucoma, there are drugs of the first (most effective and safe) and second-line treatment. First-line treatment includes prostaglandin analogs and beta-blockers. The currently used...
Gespeichert in:
| Veröffentlicht in: | Kachestvennai͡a︡ klinicheskai͡a︡ praktika H. 3; S. 44 - 54 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch Russisch |
| Veröffentlicht: |
Izdatelstvo OKI
20.10.2023
|
| Schlagworte: | |
| ISSN: | 2588-0519, 2618-8473 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Glaucoma is a disease associated with increased intraocular pressure (IOP). Of the pharmacological agents for treating glaucoma, there are drugs of the first (most effective and safe) and second-line treatment. First-line treatment includes prostaglandin analogs and beta-blockers. The currently used prostaglandin analogs (latanoprost, bimatoprost, tafluprost and travoprost) are PG F2α analogs that act through stimulation of FP receptors. They are distinguished by the optimal ratio of effectiveness and risk of side effects. They are convenient for the patient because for the therapeutic effect, it is enough to prescribe 1 time per day. As a result, it is rational to start the treatment of glaucoma with a drug in this group. In terms of pharmacoeconomics, the most affordable prostaglandin drug is latanoprost, which is generally as effective as other prostaglandin analogs. β-adrenergic blockers reduce the production of intraocular fluid, the formation of which is controlled by β1- and β2-adrenergic receptors. Therefore, non-selective β-blockers (timolol, levobunolol, metipranolol, and carteolol) have a pharmacodynamic advantage over selective β1-adrenergic antagonists (betaxolol). Conducted clinical studies of β-blockers have shown that given the cost, efficacy and safety, timolol was the most preferable treatment for glaucoma. In the presence of medical contraindications to the use of first-line drugs or to enhance their effectiveness, α2-agonists (apraclonidine and brimonidine), carbonic anhydrase inhibitors (usually local action: dorzolamide and brinzolamide), M-cholinomimetics (pilocarpine, carbachol and echothiopate), and also Rho-kinase inhibitors (ripasudil) |
|---|---|
| AbstractList | Glaucoma is a disease associated with increased intraocular pressure (IOP). Of the pharmacological agents for treating glaucoma, there are drugs of the first (most effective and safe) and second-line treatment. First-line treatment includes prostaglandin analogs and beta-blockers. The currently used prostaglandin analogs (latanoprost, bimatoprost, tafluprost and travoprost) are PG F2α analogs that act through stimulation of FP receptors. They are distinguished by the optimal ratio of effectiveness and risk of side effects. They are convenient for the patient because for the therapeutic effect, it is enough to prescribe 1 time per day. As a result, it is rational to start the treatment of glaucoma with a drug in this group. In terms of pharmacoeconomics, the most affordable prostaglandin drug is latanoprost, which is generally as effective as other prostaglandin analogs. β-adrenergic blockers reduce the production of intraocular fluid, the formation of which is controlled by β1- and β2-adrenergic receptors. Therefore, non-selective β-blockers (timolol, levobunolol, metipranolol, and carteolol) have a pharmacodynamic advantage over selective β1-adrenergic antagonists (betaxolol). Conducted clinical studies of β-blockers have shown that given the cost, efficacy and safety, timolol was the most preferable treatment for glaucoma. In the presence of medical contraindications to the use of first-line drugs or to enhance their effectiveness, α2-agonists (apraclonidine and brimonidine), carbonic anhydrase inhibitors (usually local action: dorzolamide and brinzolamide), M-cholinomimetics (pilocarpine, carbachol and echothiopate), and also Rho-kinase inhibitors (ripasudil) |
| Author | Korsakov, M. K. Popova, A. A. Khokhlov, A. I. Strakhov, V. V. Suleymanov, S. S. Fedorov, V. N. Vdovichenko, V. P. |
| Author_xml | – sequence: 1 givenname: V. N. surname: Fedorov fullname: Fedorov, V. N. organization: FSBEI НЕ "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian Federation – sequence: 2 givenname: V. P. surname: Vdovichenko fullname: Vdovichenko, V. P. organization: Grodno State Medical University – sequence: 3 givenname: M. K. surname: Korsakov fullname: Korsakov, M. K. organization: M.V. Dorogov Pharmaceutical Technology Transfer Center YSPU after K.D. Ushinsky – sequence: 4 givenname: V. V. surname: Strakhov fullname: Strakhov, V. V. organization: FSBEI НЕ "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian Federation – sequence: 5 givenname: A. A. surname: Popova fullname: Popova, A. A. organization: M.V. Dorogov Pharmaceutical Technology Transfer Center YSPU after K.D. Ushinsky – sequence: 6 givenname: A. I. orcidid: 0000-0002-0032-0341 surname: Khokhlov fullname: Khokhlov, A. I. organization: FSBEI НЕ "Yaroslavl State Medical University" of the Ministry of Healthcare of the Russian Federation – sequence: 7 givenname: S. S. surname: Suleymanov fullname: Suleymanov, S. S. organization: Russian-Japanese Medical Center "SAIKO" |
| BookMark | eNo9kNtKAzEURYNUsNZ-g_MD0VxOkpknkeKlUNAHfQ6Z5KSNdCYlU4X-vdN6eTqHzWZtWJdk0uceCbnm7EYaqJtboeqaMsUbKpiQVFIAquCMTIXmNa3ByMn4_5UuyHwYUssAjGLSmCm5e9240jmf9xssbneocqzWW_fpc-eq1Fd7LN1wDPErBew90tYNGKoOQ_KpxytyHt12wPnvnZH3x4e3xTNdvTwtF_cr6rmWQAV4KbgA7rWqmW5544RDF6LmjWg8Rm9QyxhqbGIrjAblRRsbbDGwMUY5I8sfbsjuw-5K6lw52OySPQW5rK0r--S3aMEIphkDx2oDfhwbB8yI92xcCVKNLPPD8iUPQ8H4z-PMnrTaozF7NGaPWq20AFaB_AacHmyF |
| Cites_doi | 10.1016/j.ophtha.2004.08.022 10.1177/112067210401400508 10.1097/IJG.0b013e31819c49d4 10.18240/ijo.2020.03.16 10.1097/IJG.0b013e3181666557 10.1016/S0161-6420(98)91048-X 10.1016/j.ophtha.2009.03.050 10.3109/13816810.2016.1164193 10.1001/archopht.1997.01100160017002 10.1007/s00417-005-1160-7 10.1034/j.1600-0420.1998.760618.x 10.1089/jop.2011.0245 10.1177/112067210101102S10 10.1016/j.ophtha.2005.06.020 10.1177/112067210501500508 10.1097/IJG.0b013e31815072fe 10.1016/j.ophtha.2005.10.045 10.1016/S0039-6257(01)00212-0 10.1016/j.mcna.2008.01.002 10.1080/13543776.2019.1661992 10.1016/S0039-6257(97)80009-4 10.1136/bjophthalmol-2012-302121 10.1097/ICO.0b013e3182000c27 10.1186/s12886-020-01490-1 10.1097/IJG.0b013e318133fb70 10.2147/tcrm.2006.2.4.337 10.1001/archopht.120.10.1268 10.1001/archopht.1972.01000030051011 10.1177/106002809603000109 10.1016/j.ophtha.2007.10.004 10.1016/S0002-9394(98)00286-4 10.2174/0929867325666181031102829 10.1001/archopht.122.2.185 10.1517/14656566.1.4.815 10.1016/j.ophtha.2011.01.047 10.1186/1471-2415-8-1 10.1089/jop.2004.20.383 10.1016/S0002-9394(02)01827-5 10.1007/BF02850159 10.1016/j.clinthera.2006.03.001 10.1016/j.ophtha.2014.05.013 10.1016/S0002-9394(03)00098-9 10.1016/j.ophtha.2009.01.036 10.1185/03007990903498786 10.1016/j.ophtha.2005.01.042 10.1016/j.clinthera.2008.04.006 10.1016/j.ophtha.2007.01.025 10.3389/fphar.2019.00679 10.1016/j.ajo.2003.10.035 10.1001/archopht.122.10.1543 10.1136/bjo.2008.144535 10.1185/030079907X178720 10.1089/108076802760116133 10.1001/archopht.120.6.701 10.1016/S0161-6420(00)00081-6 10.18008/1816-5095-2020-3S-542-549 10.1001/archopht.122.1.17 10.1038/eye.2001.15 10.2147/OPTH.S59162 10.1111/j.1755-3768.2010.01862.x 10.1007/BF02850299 10.1016/j.clinthera.2007.09.006 10.1580/08-WEME-LE-259R1.1 10.1111/j.1527-3466.2006.00001.x 10.1016/S0039-6257(02)00307-7 10.2165/00002512-199202030-00005 10.1089/jop.2005.21.475 10.1111/j.1346-8138.2010.00921.x 10.1016/j.ophtha.2003.09.025 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION DOA |
| DOI | 10.37489/2588-0519-2023-3-44-54 |
| DatabaseName | CrossRef Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2618-8473 |
| EndPage | 54 |
| ExternalDocumentID | oai_doaj_org_article_47206004a0874c06b29c77e6c0fc7d35 10_37489_2588_0519_2023_3_44_54 |
| GroupedDBID | AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c1634-24c321241c65806b19a2aeadf61929cefc7e63fd8e9fb27645c2bf9ebed03fde3 |
| IEDL.DBID | DOA |
| ISSN | 2588-0519 |
| IngestDate | Fri Oct 03 12:38:02 EDT 2025 Sat Nov 29 05:01:01 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English Russian |
| License | https://www.clinvest.ru/jour/about/editorialPolicies#openAccessPolicy |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1634-24c321241c65806b19a2aeadf61929cefc7e63fd8e9fb27645c2bf9ebed03fde3 |
| ORCID | 0000-0002-0032-0341 |
| OpenAccessLink | https://doaj.org/article/47206004a0874c06b29c77e6c0fc7d35 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_47206004a0874c06b29c77e6c0fc7d35 crossref_primary_10_37489_2588_0519_2023_3_44_54 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-20 |
| PublicationDateYYYYMMDD | 2023-10-20 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationTitle | Kachestvennai͡a︡ klinicheskai͡a︡ praktika |
| PublicationYear | 2023 |
| Publisher | Izdatelstvo OKI |
| Publisher_xml | – name: Izdatelstvo OKI |
| References | ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 ref53 ref52 ref11 ref55 ref10 ref54 ref17 ref16 ref19 ref18 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref86 ref41 ref85 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref82 ref81 ref40 ref84 ref83 ref80 ref35 ref79 ref34 ref78 ref37 ref36 ref31 ref75 ref30 ref74 ref33 ref77 ref32 ref76 ref2 ref1 ref39 ref38 ref71 ref70 ref73 ref72 ref24 ref68 ref23 ref67 ref26 ref25 ref69 ref20 ref64 ref63 ref22 ref66 ref21 ref65 ref28 ref27 ref29 ref60 ref62 ref61 |
| References_xml | – ident: ref22 doi: 10.1016/j.ophtha.2004.08.022 – ident: ref1 – ident: ref41 doi: 10.1177/112067210401400508 – ident: ref5 – ident: ref66 – ident: ref30 doi: 10.1097/IJG.0b013e31819c49d4 – ident: ref36 doi: 10.18240/ijo.2020.03.16 – ident: ref81 – ident: ref37 doi: 10.1097/IJG.0b013e3181666557 – ident: ref55 doi: 10.1016/S0161-6420(98)91048-X – ident: ref71 doi: 10.1016/j.ophtha.2009.03.050 – ident: ref13 doi: 10.3109/13816810.2016.1164193 – ident: ref54 doi: 10.1001/archopht.1997.01100160017002 – ident: ref62 doi: 10.1007/s00417-005-1160-7 – ident: ref65 doi: 10.1034/j.1600-0420.1998.760618.x – ident: ref76 – ident: ref9 – ident: ref43 doi: 10.1089/jop.2011.0245 – ident: ref58 doi: 10.1177/112067210101102S10 – ident: ref4 doi: 10.1016/j.ophtha.2005.06.020 – ident: ref60 doi: 10.1177/112067210501500508 – ident: ref72 doi: 10.1097/IJG.0b013e31815072fe – ident: ref82 – ident: ref18 doi: 10.1016/j.ophtha.2005.10.045 – ident: ref19 doi: 10.1016/S0039-6257(01)00212-0 – ident: ref69 doi: 10.1016/j.mcna.2008.01.002 – ident: ref75 – ident: ref12 doi: 10.1080/13543776.2019.1661992 – ident: ref15 doi: 10.1016/S0039-6257(97)80009-4 – ident: ref47 – ident: ref44 doi: 10.1136/bjophthalmol-2012-302121 – ident: ref79 – ident: ref27 doi: 10.1097/ICO.0b013e3182000c27 – ident: ref86 doi: 10.1186/s12886-020-01490-1 – ident: ref17 doi: 10.1097/IJG.0b013e318133fb70 – ident: ref53 doi: 10.2147/tcrm.2006.2.4.337 – ident: ref7 doi: 10.1001/archopht.120.10.1268 – ident: ref83 – ident: ref77 doi: 10.1001/archopht.1972.01000030051011 – ident: ref45 doi: 10.1177/106002809603000109 – ident: ref33 doi: 10.1016/j.ophtha.2007.10.004 – ident: ref57 doi: 10.1016/S0002-9394(98)00286-4 – ident: ref85 doi: 10.2174/0929867325666181031102829 – ident: ref48 doi: 10.1001/archopht.122.2.185 – ident: ref56 doi: 10.1517/14656566.1.4.815 – ident: ref74 – ident: ref2 doi: 10.1016/j.ophtha.2011.01.047 – ident: ref25 doi: 10.1186/1471-2415-8-1 – ident: ref40 doi: 10.1089/jop.2004.20.383 – ident: ref24 doi: 10.1016/S0002-9394(02)01827-5 – ident: ref23 doi: 10.1007/BF02850159 – ident: ref50 doi: 10.1016/j.clinthera.2006.03.001 – ident: ref3 doi: 10.1016/j.ophtha.2014.05.013 – ident: ref16 doi: 10.1016/S0002-9394(03)00098-9 – ident: ref31 doi: 10.1016/j.ophtha.2009.01.036 – ident: ref32 doi: 10.1185/03007990903498786 – ident: ref35 doi: 10.1016/j.ophtha.2005.01.042 – ident: ref38 doi: 10.1016/j.clinthera.2008.04.006 – ident: ref51 doi: 10.1016/j.ophtha.2007.01.025 – ident: ref73 doi: 10.3389/fphar.2019.00679 – ident: ref42 doi: 10.1016/j.ajo.2003.10.035 – ident: ref67 doi: 10.1001/archopht.122.10.1543 – ident: ref84 – ident: ref20 doi: 10.1136/bjo.2008.144535 – ident: ref34 doi: 10.1185/030079907X178720 – ident: ref64 doi: 10.1089/108076802760116133 – ident: ref8 doi: 10.1001/archopht.120.6.701 – ident: ref59 doi: 10.1016/S0161-6420(00)00081-6 – ident: ref63 doi: 10.18008/1816-5095-2020-3S-542-549 – ident: ref26 doi: 10.1001/archopht.122.1.17 – ident: ref80 – ident: ref78 doi: 10.1038/eye.2001.15 – ident: ref49 – ident: ref14 doi: 10.2147/OPTH.S59162 – ident: ref52 – ident: ref29 doi: 10.1111/j.1755-3768.2010.01862.x – ident: ref21 doi: 10.1007/BF02850299 – ident: ref28 doi: 10.1016/j.clinthera.2007.09.006 – ident: ref68 doi: 10.1580/08-WEME-LE-259R1.1 – ident: ref11 doi: 10.1111/j.1527-3466.2006.00001.x – ident: ref39 doi: 10.1016/S0039-6257(02)00307-7 – ident: ref46 doi: 10.2165/00002512-199202030-00005 – ident: ref61 doi: 10.1089/jop.2005.21.475 – ident: ref10 – ident: ref70 doi: 10.1111/j.1346-8138.2010.00921.x – ident: ref6 doi: 10.1016/j.ophtha.2003.09.025 |
| SSID | ssib044750377 ssj0002874179 |
| Score | 2.2351115 |
| Snippet | Glaucoma is a disease associated with increased intraocular pressure (IOP). Of the pharmacological agents for treating glaucoma, there are drugs of the first... |
| SourceID | doaj crossref |
| SourceType | Open Website Index Database |
| StartPage | 44 |
| SubjectTerms | альфа-2 адреномиметики аналоги простагландинов бета-адреноблокаторы внутриглазное давление глаукома закрытоугольная глаукома открытоугольная ингибиторы карбоангидразы |
| Title | Pharmacotherapy of glaucoma in terms of evidence-based medicine |
| URI | https://doaj.org/article/47206004a0874c06b29c77e6c0fc7d35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2618-8473 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0002874179 issn: 2588-0519 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2618-8473 dateEnd: 99991231 omitProxy: false ssIdentifier: ssib044750377 issn: 2588-0519 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09T8MwELVQhRAL4lN8KwOrVce-xMmEALVioFUHQN0sx7GlMrSoH0gs_HbunLTqxsKS4ZRE0btT3rvEfsfYnfWghJMZ9ibYrkIlFS9ssBy5xNZe-6yOe2HeX_RwWIzH5Whr1BetCWvsgRvguqClQFIGKwoNTuSVLJ3WPnciOF2r6F6KqmermcJKIhc7ododlh_xE5KmUVs0aS7D0iDd0iz2iu4r3U2Q0zRxrjhAHBCwRVVbjv6RevqH7KDVjMlD86xHbGe-OmZ7g_av-Am7H7X-081mqu9kFhJUxSssJptMpgm9fRcU9O0IUU7cVSfr_-qn7K3fe3165u1gBO5QPgGX4BRSDqQO9QNCkpZWWiyJQN1Q6Twi43MV6sKXoZI6h8zJKpSYr1pg2Ksz1pnOpv6cJSBsXSkUJUVIEaGiKK1HOCFkqbLKwgUTawzMZ-N_YbBviLAZgs0QbIZgM8oAmAwveSSsNqeTgXUMYFpNm1bzV1ov_-MmV2w_5hOpRopr1lnOV_6G7bqv5WQxv40Vg8fBT-8XIYO9zA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacotherapy+of+glaucoma+in+terms+of+evidence-based+medicine&rft.jtitle=Kachestvennai%CD%A1a%EF%B8%A1+klinicheskai%CD%A1a%EF%B8%A1+praktika&rft.au=V.+N.+Fedorov&rft.au=V.+P.+Vdovichenko&rft.au=M.+K.+Korsakov&rft.au=V.+V.+Strakhov&rft.date=2023-10-20&rft.pub=Izdatelstvo+OKI&rft.issn=2588-0519&rft.eissn=2618-8473&rft.issue=3&rft.spage=44&rft.epage=54&rft_id=info:doi/10.37489%2F2588-0519-2023-3-44-54&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_47206004a0874c06b29c77e6c0fc7d35 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2588-0519&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2588-0519&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2588-0519&client=summon |